STOCK TITAN
  1. Home
  2. News
  3. KYMR

Kymera Therapeutics, Inc. - KYMR STOCK NEWS

Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.

Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a biotechnology company harnessing the power of targeted protein degradation (TPD) to develop transformative treatments for previously untreatable diseases. Founded in 2016, and headquartered in Watertown, Massachusetts, Kymera is at the forefront of biotechnology, utilizing the body's innate protein recycling machinery to degrade disease-causing proteins rather than merely inhibiting them.

The company's pioneering platform, Pegasus™, leverages proprietary predictive modeling and an integrated degradation approach to address disease targets previously deemed intractable. This novel modality allows Kymera to target and degrade proteins involved in various critical pathways, including those in immunological diseases and oncology. Key drugs in their pipeline include:

  • KT-474: An IRAK4 degrader currently in Phase 2 trials for immuno-inflammatory conditions.
  • KT-333: A STAT3 degrader in Phase 1 trials, targeting hematological malignancies and solid tumors.
  • KT-253: An MDM2 degrader undergoing Phase 1 trials, aimed at cancers with p53 pathway involvement.
  • KT-621: A STAT6 degrader poised to enter Phase 1 trials, showing promising preclinical results for treating TH2-driven diseases like asthma and atopic dermatitis.

Kymera's achievements include successful partnerships with leading pharmaceutical companies such as Sanofi, ongoing collaborations with research institutions, and securing significant financial backing with over $745 million in cash reserves to support operations into 2027. The company's innovative approach and robust pipeline have earned it recognition as one of Boston’s top workplaces.

Kymera continues to make significant strides in drug discovery and development, with a focus on delivering highly effective, convenient oral therapies. Recent updates include positive preclinical and clinical data presentations at major medical conferences, highlighting the potential of their degradation technology to revolutionize treatment paradigms across various diseases.

For more information, visit Kymera Therapeutics or follow them on X (formerly Twitter) and LinkedIn.

News

Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine

Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced positive Phase 1 clinical trial results for KT-474 (SAR444656), a potent IRAK4 degrader, published in Nature Medicine. The trial demonstrated robust target degradation and pathway inhibition, with a favorable safety profile, encouraging impact on disease burden and symptoms in Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD), and a systemic anti-inflammatory effect in patients. KT-474's unique potential in treating inflammatory diseases was highlighted, with promising Phase 2 clinical trials conducted by Sanofi. The publication also included preclinical data and chemical structure details of KT-474.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
clinical trial
-
News

Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting

Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced the release of new Phase 1 data for their KT-333 drug at the ASH 65th Annual Meeting and Exposition. The data includes safety, pharmacokinetics, pharmacodynamics, and clinical responses. The abstract reported positive results, including a partial response in a CTCL patient and stable disease in three solid tumor patients. No dose limiting toxicities or serious adverse events were reported. The presentation will also include preclinical data supporting the potential of STAT3 protein degraders in venetoclax-resistant Acute Myeloid Leukemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
conferences clinical trial
-
News

Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update

Rhea-AI Summary
Kymera Therapeutics reported financial results for Q3 2023 and provided updates on its protein degraders pipeline. The company achieved a $40 million milestone payment from Sanofi for the initiation of Phase 2 trials of KT-474/SAR444656. The Phase 2 trial for KT-474 in atopic dermatitis is expected to begin in Q4 2023. KT-333 (STAT3) showed signs of anti-tumor activity in liquid and solid tumor types. KT-253 (MDM2) achieved clinical proof-of-mechanism and demonstrated anti-tumor activity in solid tumor patients. Development of KT-413 (IRAKIMiD) will be discontinued. Kymera will focus on its immunology pipeline and will hold a virtual Immunology R&D Day on January 4, 2024. The company has a cash balance of $435 million, providing a runway into H1 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
earnings
News

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

Rhea-AI Summary
Kymera Therapeutics, Inc. will participate in several upcoming investor events, including TD Cowen 7th Annual Virtual Fall Oncology Innovation Summit, UBS Biopharma Conference, Stifel 2023 Healthcare Conference, Piper Sandler 35th Annual Healthcare Conference, and Evercore ISI 6th Annual HealthCONx Conference. Live webcasts and replays of the fireside chats will be available on the company's website. The company will also host one-on-one meetings at the J.P. Morgan Equity Opportunities Forum and the Truist Securities BioPharma Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
conferences
-
News

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi

Rhea-AI Summary
Kymera Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial for hidradenitis suppurativa (HS) using their investigational IRAK4 degrader, KT-474. The trial will evaluate the efficacy and safety of KT-474 compared to placebo in adult patients with moderate to severe HS. The initiation of dosing in this trial has generated a milestone payment of $40 million for Kymera.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags
clinical trial
-
News

Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2

Rhea-AI Summary
Kymera Therapeutics, Inc. will report its Q3 2023 financial results on November 2, 2023, and will host a conference call. The live webcast will be available on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
conferences earnings
News

Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma

Rhea-AI Summary
Kymera Therapeutics (NASDAQ: KYMR) announced that the FDA has granted Fast Track designation to KT-333 for the treatment of R/R Cutaneous T-cell Lymphoma (CTCL) and R/R Peripheral T-cell Lymphoma (PTCL).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
clinical trial
-
News

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Rhea-AI Summary
Kymera Therapeutics to participate in investor events
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
conferences
-
News

Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update

Rhea-AI Summary
KT-474/SAR444656 Phase 2 trials for HS and AD planned to start in 4Q23. Cash balance of $472 million with runway into 2H25. Quarterly results call held. KT-253 Phase 1 trials ongoing. KT-333 and KT-413 degraders showed anti-tumor activity. Sanofi to initiate Phase 2 trials for KT-474. New COO and Head of Investor Relations appointed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.07%
Tags
earnings
News

Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3

Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) to report Q2 2023 financial results on August 3, 2023. The company focuses on advancing targeted protein degradation for small molecule protein degrader medicines. Conference call details and webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
conferences earnings

FAQ

What is the current stock price of Kymera Therapeutics (KYMR)?

The current stock price of Kymera Therapeutics (KYMR) is $40.66 as of December 20, 2024.

What is the market cap of Kymera Therapeutics (KYMR)?

The market cap of Kymera Therapeutics (KYMR) is approximately 2.5B.

What is Kymera Therapeutics' main focus?

Kymera Therapeutics focuses on developing treatments for previously untreatable diseases using targeted protein degradation to eliminate disease-causing proteins.

What is the Pegasus platform?

Pegasus is Kymera's proprietary platform that leverages predictive modeling and integrated degradation technologies to target and degrade intractable disease-causing proteins.

What are some key drugs in Kymera's pipeline?

Key drugs include KT-474 (IRAK4 degrader), KT-333 (STAT3 degrader), KT-253 (MDM2 degrader), and KT-621 (STAT6 degrader).

What diseases is Kymera targeting?

Kymera is targeting a range of diseases including immuno-inflammatory conditions, various forms of cancer, and TH2-mediated diseases like asthma.

What recent achievements has Kymera made?

Recent achievements include positive preclinical and clinical data, significant partnerships, and financial backing to support operations into 2027.

How does Kymera's technology differ from conventional therapies?

Kymera's technology degrades disease-causing proteins rather than merely inhibiting them, offering potentially more effective and lasting treatments.

Who are Kymera's partners?

Kymera has partnered with leading pharmaceutical companies such as Sanofi and collaborates with various research institutions.

Where is Kymera Therapeutics headquartered?

Kymera Therapeutics is headquartered in Watertown, Massachusetts.

How is Kymera funded?

Kymera has over $745 million in cash reserves, supporting operations and research efforts through various financial backings and a recent equity offering.

Where can I find more information about Kymera?

More information can be found on Kymera's website (www.kymeratx.com) and their official social media profiles on X (formerly Twitter) and LinkedIn.

Stock KYMR logo
Kymera Therapeutics, Inc.

Nasdaq:KYMR

KYMR Rankings

#1784 Ranked by Market Cap
N/A Ranked by Dividends

KYMR Stock Data

2.54B
63.89M
1.27%
108.43%
14.09%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WATERTOWN